The DOI matches its Crossref record; 144 of the 144 references it cites were found in a registry or an index.
Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Arzneimittelforschung: Erstanwendung am Menschen in der Phase I
Miletzki, B., & Gleiter, C. H. (2005) · Bundesgesundheitsblatt Gesundheitsforsch.Gesundheitsschutz · doi:10.1007/s00103-005-1024-7 · Cited by 9,355
Black, D. M., Cummings, S. R., Karpf, D. B., Cauley, J. A., Thompson, D. E., Nevitt, M. C., Bauer, D. C., Genant, H. K., Haskell, W. L., Marcus, R., et al. (1996) · The Lancet · doi:10.1016/s0140-6736(96)07088-2 · Cited by 3,846
Once-Yearly Zoledronic Acid for Treatment of Postmenopausal Osteoporosis
Black, D. M., Delmas, P. D., Eastell, R., Reid, I. R., Boonen, S., Cauley, J. A., Cosman, F., Lakatos, P., Leung, P. C., Man, Z., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa067312 · Cited by 2,986
Liberman, U. A., Weiss, S. R., Bröll, J., Minne, H. W., Quan, H., Bell, N. H., Rodriguez-Portales, J., Downs, R. W., Dequeker, J., Favus, M., et al. (1995) · New England Journal of Medicine · doi:10.1056/nejm199511303332201 · Cited by 2,288
Zoledronic Acid and Clinical Fractures and Mortality after Hip Fracture
Lyles, K. W., Colón-Emeric, C. S., Magaziner, J. S., Adachi, J. D., Pieper, C. F., Mautalen, C., Hyldstrup, L., Recknor, C., Nordsletten, L., Moore, K. A., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa074941 · Cited by 2,003 · cited 2×
“A further trial with once yearly IV zoledronate in patients after hip fracture showed that prevention of further nonvertebral fractures could be significantly reduced [136].”
BackgroundEffect of Risedronate on the Risk of Hip Fracture in Elderly Women
McClung, M. R., Geusens, P., Miller, P. D., Zippel, H., Bensen, W. G., Roux, C., Adami, S., Fogelman, I., Diamond, T., Eastell, R., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200102013440503 · Cited by 1,918
Reginster, J.-Y., Minne, H. W., Sorensen, O. H., Hooper, M., Roux, C., Brandi, M. L., Lund, B., Ethgen, D., Pack, S., Roumagnac, I., et al. (2000) · Osteoporosis International · doi:10.1007/s001980050010 · Cited by 1,580
Severely Suppressed Bone Turnover: A Potential Complication of Alendronate Therapy
Odvina, C. V., Zerwekh, J. E., Rao, D. S., Maalouf, N., Gottschalk, F. A., & Pak, C. Y. C. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2004-0952 · Cited by 1,432
Black, D. M., Schwartz, A. V., Ensrud, K. E., Cauley, J. A., Levis, S., Quandt, S. A., Satterfield, S., Wallace, R. B., Bauer, D. C., Palermo, L., et al. (2006) · JAMA · doi:10.1001/jama.296.24.2927 · Cited by 1,407
Ten Years' Experience with Alendronate for Osteoporosis in Postmenopausal Women
Bone, H. G., Hosking, D., Devogelaer, J.-P., Tucci, J. R., Emkey, R. D., Tonino, R. P., Rodriguez-Portales, J. A., Downs, R. W., Gupta, J., Santora, A. C., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa030897 · Cited by 1,347
Chesnut, C. H., Skag, A., Christiansen, C., Recker, R., Stakkestad, J. A., Hoiseth, A., Felsenberg, D., Huss, H., Gilbride, J., Schimmer, R. C., et al. (2004) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.040325 · Cited by 1,229
Luckman, S. P., Hughes, D. E., Coxon, F. P., Russell, R. G. G., & Dr. Rogers, M. J. (1998) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.1998.13.4.581 · Cited by 1,176
Self-citationBlack, D. M., Greenspan, S. L., Ensrud, K. E., Palermo, L., McGowan, J. A., Lang, T. F., Garnero, P., Bouxsein, M. L., Bilezikian, J. P., & Rosen, C. J. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa031975 · Cited by 1,174
Sato, M., Grasser, W., Endo, N., Akins, R., Simmons, H., Thompson, D. D., Golub, E., & Rodan, G. A. (1991) · Journal of Clinical Investigation · doi:10.1172/jci115539 · Cited by 1,004
Fracture Risk Reduction with Alendronate in Women with Osteoporosis: The Fracture Intervention Trial
Black, D. M., Thompson, D. E., Bauer, D. C., Ensrud, K., Musliner, T., Hochberg, M. C., Nevitt, M. C., Suryawanshi, S., & Cummings, S. R. (2000) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.85.11.6953 · Cited by 982
Intermittent Cyclical Etidronate Treatment of Postmenopausal Osteoporosis
Watts, N. B., Harris, S. T., Genant, H. K., Wasnich, R. D., Miller, P. D., Jackson, R. D., Licata, A. A., Ross, P., Woodson, G. C., Yanover, M. J., et al. (1990) · New England Journal of Medicine · doi:10.1056/nejm199007123230201 · Cited by 949
Self-citationStorm, T., Thamsborg, G., Steiniche, T., Genant, H. K., & Sorensen, O. H. (1990) · New England Journal of Medicine · doi:10.1056/nejm199005033221803 · Cited by 935
Bisphosphonates: A review of their pharmacokinetic properties
Lin, J. H. (1996) · Bone · doi:10.1016/8756-3282(95)00445-9 · Cited by 932
Dunford, J. E., Thompson, K., Coxon, F. P., Luckman, S. P., Hahn, F. M., Poulter, C. D., Ebetino, F. H., & Rogers, M. J. (2001) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)38786-5 · Cited by 900
Self-citationPrevention of osteocyte and osteoblast apoptosis by bisphosphonates and calcitonin
Plotkin, L. I., Weinstein, R. S., Parfitt, A. M., Roberson, P. K., Manolagas, S. C., & Bellido, T. (1999) · Journal of Clinical Investigation · doi:10.1172/jci6800 · Cited by 890 · cited 1×
“Very low concentrations of many BPs appear to protect osteocytes (and osteoblasts) from apoptosis induced by glucocorticoids in vitro [65].”
BackgroundIntravenous Zoledronic Acid in Postmenopausal Women with Low Bone Mineral Density
Reid, I. R., Brown, J. P., Burckhardt, P., Horowitz, Z., Richardson, P., Trechsel, U., Widmer, A., Devogelaer, J.-P., Kaufman, J.-M., Jaeger, P., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa011807 · Cited by 877
Nancollas, G. H., Tang, R., Phipps, R. J., Henneman, Z., Gulde, S., Wu, W., Mangood, A., Russell, R. G. G., & Ebetino, F. H. (2006) · Bone · doi:10.1016/j.bone.2005.05.003 · Cited by 862 · cited 9×
“Asterisk The alendronate data are from the highest concentration tested (~3 μmol) [24] Osteoporos Int (2008) 19:733–759 739”
BackgroundMethodResultInfluentialSelf-citationFleisch, H., Graham, R., Russell, G., & Francis, M. D. (1969) · Science · doi:10.1126/science.165.3899.1262 · Cited by 758
Garrison, L. P., Neumann, P. J., Erickson, P., Marshall, D., & Mullins, C. D. (2007) · Value in Health · doi:10.1111/j.1524-4733.2007.00186.x · Cited by 700
EFFECT OF RISEDRONATE ON THE RISK OF HIP FRACTURE IN ELDERLY WOMEN
Lung, R. M. C. C., Eusens, P. I. G., Aul, P., Iller, D. M., Ippel, H. A. Z., Ensen, W. I. G. B., Oux, C. H. R., Dami, S. I. A., Ogelman, I. G. F., Astell, R. I. E., et al. (2001) · Cited by 682
Fisher, J. E., Rogers, M. J., Halasy, J. M., Luckman, S. P., Hughes, D. E., Masarachia, P. J., Wesolowski, G., Russell, R. G. G., Rodan, G. A., & Reszka, A. A. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.1.133 · Cited by 676
Self-citationFrancis, M. D., Graham, R., Russell, G., & Fleisch, H. (1969) · Science · doi:10.1126/science.165.3899.1264 · Cited by 608
Pols, H. A. P., Felsenberg, D., Hanley, D. A., Štepán, J., Muñoz-Torres, M., Wilkin, T. J., Qin-sheng, G., Galich, A. M., Vandormael, K., Yates, A. J., et al. (1999) · Osteoporosis International · doi:10.1007/pl00004171 · Cited by 593
Relationship of Early Changes in Bone Resorption to the Reduction in Fracture Risk With Risedronate
Eastell, R., Barton, I., Hannon, R., Chines, A., Garnero, P., & Delmas, P. (2003) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.2003.18.6.1051 · Cited by 588
New Insights Into the Molecular Mechanisms of Action of Bisphosphonates
Rogers, M. (2003) · Current Pharmaceutical Design · doi:10.2174/1381612033453640 · Cited by 579
Self-citationThe molecular mechanism of nitrogen-containing bisphosphonates as antiosteoporosis drugs
Kavanagh, K. L., Guo, K., Dunford, J. E., Wu, X., Knapp, S., Ebetino, F. H., Rogers, M. J., Russell, R. G. G., & Oppermann, U. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0601643103 · Cited by 536
Self-citationChavassieux, P. M., Arlot, M. E., Reda, C., Wei, L., Yates, A. J., & Meunier, P. J. (1997) · Journal of Clinical Investigation · doi:10.1172/jci119668 · Cited by 523
Farnesyl Pyrophosphate Synthase Is the Molecular Target of Nitrogen-Containing Bisphosphonates
van Beek, E., Pieterman, E., Cohen, L., Löwik, C., & Papapoulos, S. (1999) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1999.1499 · Cited by 496
Aguirre, J. I., Plotkin, L. I., Stewart, S. A., Weinstein, R. S., Parfitt, A. M., Manolagas, S. C., & Bellido, T. (2006) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.060107 · Cited by 494
A systematic review of the role of bisphosphonates in metastatic disease
Ross, J., Saunders, Y., Edmonds, P., Patel, S., Wonderling, D., Normand, C., & Broadley, K. (2004) · Health Technology Assessment · doi:10.3310/hta8040 · Cited by 467
Bisphosphonate-Induced Osteopetrosis
Whyte, M. P., Wenkert, D., Clements, K. L., McAlister, W. H., & Mumm, S. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa023110 · Cited by 446
Comparison of a Single Infusion of Zoledronic Acid with Risedronate for Paget's Disease
Reid, I. R., Miller, P., Lyles, K., Fraser, W., Brown, J. P., Saidi, Y., Mesenbrink, P., Su, G., Pak, J., Zelenakas, K., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa044241 · Cited by 439
Frith, J. C., Mönkkönen, J., Blackburn, G. M., Russell, R. G. G., & Rogers, M. J. (1997) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.1997.12.9.1358 · Cited by 437
Self-citationOsteocytes as Dynamic Multifunctional Cells
BONEWALD, L. F. (2007) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1402.018 · Cited by 417
Bisphosphonates act on rat bone resorption through the mediation of osteoblasts.
Sahni, M., Guenther, H. L., Fleisch, H., Collin, P., & Martin, T. J. (1993) · Journal of Clinical Investigation · doi:10.1172/jci116422 · Cited by 412
Bisphosphonates: From Bench to Bedside
RUSSELL, R. G. G. (2006) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1346.041 · Cited by 410
Self-citationAlendronate Is a Specific, Nanomolar Inhibitor of Farnesyl Diphosphate Synthase
Bergstrom, J. D., Bostedor, R. G., Masarachia, P. J., Reszka, A. A., & Rodan, G. (2000) · Archives of Biochemistry and Biophysics · doi:10.1006/abbi.1999.1502 · Cited by 402
Balena, R., Toolan, B. C., Shea, M., Markatos, A., Myers, E. R., Lee, S. C., Opas, E. E., Seedor, J. G., Klein, H., & Frankenfield, D. (1993) · Journal of Clinical Investigation · doi:10.1172/jci116872 · Cited by 396 · cited 1×
“long-term use [114–120].”
Bisphosphonates: An Update on Mechanisms of Action and How These Relate to Clinical Efficacy
RUSSELL, R. G. G., XIA, Z., DUNFORD, J. E., OPPERMANN, U., KWAASI, A., HULLEY, P. A., KAVANAGH, K. L., TRIFFITT, J. T., LUNDY, M. W., PHIPPS, R. J., et al. (2007) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1402.089 · Cited by 391
Self-citationPharmacokinetics and Pharmacodynamics of Zoledronic Acid in Cancer Patients with Bone Metastases
Chen, T., Berenson, J., Vescio, R., Swift, R., Gilchick, A., Goodin, S., LoRusso, P., Ma, P., Ravera, C., Deckert, F., et al. (2002) · The Journal of Clinical Pharmacology · doi:10.1177/009127002762491316 · Cited by 374
Dr. Coxon, F. P., Helfrich, M. H., Van't Hof, R., Sebti, S., Ralston, S. H., Hamilton, A., & Rogers, M. J. (2000) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.2000.15.8.1467 · Cited by 361
Self-citationRosen, C. J., Hochberg, M. C., Bonnick, S. L., McClung, M., Miller, P., Broy, S., Kagan, R., Chen, E., Petruschke, R. A., Thompson, D. E., et al. (2005) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.040920 · Cited by 345
Recker, R., Lappe, J., Davies, K. M., & Heaney, R. (2004) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.040710 · Cited by 343
Russell, R. G. G., Mühlbauer, R. C., Bisaz, S., Williams, D. A., & Fleisch, H. (1970) · Calcified Tissue Research · doi:10.1007/bf02196199 · Cited by 341
Self-citationLehenkari, P. P., Kellinsalmi, M., Näpänkangas, J. P., Ylitalo, K. V., Mönkkönen, J., Rogers, M. J., Azhayev, A., Väänänen, H. K., & Hassinen, I. E. (2002) · Molecular Pharmacology · doi:10.1016/s0026-895x(24)12222-5 · Cited by 333
Self-citationLai, K.-A. (2005) · The Journal of Bone and Joint Surgery (American) · doi:10.2106/jbjs.d.02959 · Cited by 332
Delmas, P. D., & Seeman, E. (2004) · Bone · doi:10.1016/j.bone.2003.12.022 · Cited by 294
Elimination and Biochemical Responses to Intravenous Alendronate in Postmenopausal Osteoporosis
Khan, S. A., Kanis, J. A., Vasikaran, S., Kline, W. F., Matuszewski, B. K., McCloskey, E. V., Beneton, M. N. C., Gertz, B. J., Sciberras, D. G., Holland, S. D., et al. (1997) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.1997.12.10.1700 · Cited by 293
Pressor Attacks during Treatment with Monoamine-oxidase Inhibitors
(1965) · The Lancet · doi:10.1016/s0140-6736(65)91261-4 · Cited by 286
Prevention of Nonvertebral Fractures by Alendronate: A Meta-analysis
Karpf, D. B. (1997) · JAMA · doi:10.1001/jama.1997.03540380073035 · Cited by 281
Mönkkönen, H., Auriola, S., Lehenkari, P., Kellinsalmi, M., Hassinen, I. E., Vepsäläinen, J., & Mönkkönen, J. (2006) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0706628 · Cited by 280
Luckman, S. P., Coxon, F. P., Ebetino, F. H., Russell, R. G. G., & Rogers, M. J. (1998) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.1998.13.11.1668 · Cited by 272
Self-citationStructural Basis for Bisphosphonate-mediated Inhibition of Isoprenoid Biosynthesis
Hosfield, D. J., Zhang, Y., Dougan, D. R., Broun, A., Tari, L. W., Swanson, R. V., & Finn, J. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.c300511200 · Cited by 272
Frith, J. C., M�nkk�nen, J., Auriola, S., M�nkk�nen, H., & Rogers, M. J. (2001) · Arthritis & Rheumatism · doi:10.1002/1529-0131(200109)44:9<2201::aid-art374>3.0.co;2-e · Cited by 268
Self-citationRecent advances in understanding the mechanism of action of bisphosphonates
COXON, F., THOMPSON, K., & ROGERS, M. (2006) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2006.03.005 · Cited by 252
Self-citationComparison of the distribution of 3H-alendronate and 3H-Etidronate in rat and mouse bones
Masarachia, P., Weinreb, M., Balena, R., & Rodan, G. A. (1996) · Bone · doi:10.1016/8756-3282(96)00182-2 · Cited by 248
Thompson, K., Rogers, M. J., Coxon, F. P., & Crockett, J. C. (2006) · Molecular Pharmacology · doi:10.1124/mol.105.020776 · Cited by 242
Self-citationLong-Term Safety of Bisphosphonates
Ott, S. M. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-0057 · Cited by 241
Van Beek, E., Löwik, C., Van Der Pluijm, G., & Papapoulos, S. (1999) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.1999.14.5.722 · Cited by 237
Fracture risk remains reduced one year after discontinuation of risedronate
Watts, N. B., Chines, A., Olszynski, W. P., McKeever, C. D., McClung, M. R., Zhou, X., & Grauer, A. (2008) · Osteoporosis International · doi:10.1007/s00198-007-0460-7 · Cited by 237
Self-citationVisualization of bisphosphonate-induced caspase-3 activity in apoptotic osteoclasts in vitro
Benford, H. L., McGowan, N. W. A., Helfrich, M. H., Nuttall, M. E., & Rogers, M. J. (2001) · Bone · doi:10.1016/s8756-3282(01)00412-4 · Cited by 235
Self-citationWatts, N. B., Cooper, C., Lindsay, R., Eastell, R., Manhart, M. D., Barton, I. P., van Staa, T.-P., & Adachi, J. D. (2004) · Journal of Clinical Densitometry · doi:10.1385/jcd:7:3:255 · Cited by 229
Self-citationDaubine, F., Le Gall, C., Gasser, J., Green, J., & Clezardin, P. (2007) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djk054 · Cited by 226
Structural Basis for the Exceptional in vivo Efficacy of Bisphosphonate Drugs
Rondeau, J., Bitsch, F., Bourgier, E., Geiser, M., Hemmig, R., Kroemer, M., Lehmann, S., Ramage, P., Rieffel, S., Strauss, A., et al. (2006) · ChemMedChem · doi:10.1002/cmdc.200500059 · Cited by 226
Harrington, J. T., Ste-Marie, L. G., Brandi, M. L., Civitelli, R., Fardellone, P., Grauer, A., Barton, I., & Boonen, S. (2004) · Calcified Tissue International · doi:10.1007/s00223-003-0042-4 · Cited by 223
Statins Prevent Bisphosphonate-Induced γ,δ-T-Cell Proliferation and Activation In Vitro
Thompson, K., & Rogers, M. J. (2004) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.0301230 · Cited by 217
Self-citationEriksen, E. F., Melsen, F., Sod, E., Barton, I., & Chines, A. (2002) · Bone · doi:10.1016/s8756-3282(02)00869-4 · Cited by 211
DIPHOSPHONATES AND PAGET'S DISEASE OF BONE
SMITH (1971) · The Lancet · doi:10.1016/s0140-6736(71)91447-4 · Cited by 203
McCloskey, E. V., Beneton, M., Charlesworth, D., Kayan, K., de Takats, D., Dey, A., Orgee, J., Ashford, R., Forster, M., Cliffe, J., et al. (2007) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.061008 · Cited by 200
Parfitt, A. M. (1976) · Metabolism · doi:10.1016/0026-0495(76)90151-7 · Cited by 196
The use of whole-body retention of Tc-99m diphosphonate in the diagnosis of metabolic bone disease.
Fogelman, I., Bessent, R. G., Turner, J. G., Citrin, D. L., Boyle, I. T., & Greig, W. R. (1978) · PubMed · Cited by 192
Dunford, J. E., Rogers, M. J., Ebetino, F. H., Phipps, R. J., & Coxon, F. P. (2006) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.060118 · Cited by 189
Self-citationDose-Response Relationships for Alendronate Treatment in Osteoporotic Elderly Women1
Bone, H. G., Downs, R. W., Tucci, J. R., Harris, S. T., Weinstein, R. S., Licata, A. A., McClung, M. R., Kimmel, D. B., Gertz, B. J., Hale, E., et al. (1997) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.82.1.3682 · Cited by 189
Differentiating the mechanisms of antiresorptive action of nitrogen containing bisphosphonates
van Beek, E. R., Cohen, L. H., Leroy, I. M., Ebetino, F. H., Löwik, C. W. G. M., & Papapoulos, S. E. (2003) · Bone · doi:10.1016/j.bone.2003.07.007 · Cited by 184
Self-citationEfficacy of risedronate on clinical vertebral fractures within six months
Roux, C., Seeman, E., Eastell, R., Adachi, J., Jackson, R. D., Felsenberg, D., Songcharoen, S., Rizzoli, R., Munno, O. D., Horlait, S., et al. (2004) · Current Medical Research and Opinion · doi:10.1185/030079903125003125 · Cited by 184
Self-citationDIPHOSPHONATES IN THE TREATMENT OF MYOSITIS OSSIFICANS
Bassett, C. A. L., Donath, A., Macagno, F., Preisig, R., Fleisch, H. A., & Francis, M. D. (1969) · The Lancet · doi:10.1016/s0140-6736(69)92293-4 · Cited by 182
Sirohi, B., & Powles, R. (2004) · The Lancet · doi:10.1016/s0140-6736(04)15736-x · Cited by 181
Price, P. A., Thomas, G. R., Pardini, A. W., Figueira, W. F., Caputo, J. M., & Williamson, M. K. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m106366200 · Cited by 179
Boonen, S., Laan, R., Barton, I. P., & Watts, N. B. (2005) · Osteoporosis International · doi:10.1007/s00198-005-1945-x · Cited by 177
Self-citationMcClung, M., Recker, R., Miller, P., Fiske, D., Minkoff, J., Kriegman, A., Zhou, W., Adera, M., & Davis, J. (2007) · Bone · doi:10.1016/j.bone.2007.03.011 · Cited by 176
Papapoulos, S. E., Quandt, S. A., Liberman, U. A., Hochberg, M. C., & Thompson, D. E. (2004) · Osteoporosis International · doi:10.1007/s00198-004-1725-z · Cited by 175
Silverman, S. L., Watts, N. B., Delmas, P. D., Lange, J. L., & Lindsay, R. (2007) · Osteoporosis International · doi:10.1007/s00198-006-0274-z · Cited by 174
Self-citationKavanagh, K. L., Dunford, J. E., Bunkòczi, G., Russell, R. G. G., & Oppermann, U. C. T. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m602603200 · Cited by 166
Self-citationRogers, M. J. (2004) · Calcified Tissue International · doi:10.1007/s00223-004-0024-1 · Cited by 164
Self-citationWatts, N. B., Geusens, P., Barton, I. P., & Felsenberg, D. (2005) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.050814 · Cited by 164
Self-citationPlotkin, L. I., Manolagas, S. C., & Bellido, T. (2006) · Bone · doi:10.1016/j.bone.2006.02.060 · Cited by 162
Reitsma, P. H., Bijvoet, O. L. M., Verlinden-Ooms, H., & van der Wee-Pals, L. J. A. (1980) · Calcified Tissue International · doi:10.1007/bf02408534 · Cited by 161
Black, D. M., Greenspan, S. L., Ensrud, K. E., Palermo, L., McGowan, J. A., Lang, T. F., Garnero, P., Bouxsein, M. L., Bilezikian, J. P., & Rosen, C. J. (2004) · Obstetrical & Gynecological Survey · doi:10.1097/01.ogx.0000115856.54444.d6 · Cited by 159
Parfitt, A. M. (1976) · Metabolism · doi:10.1016/0026-0495(76)90024-x · Cited by 158
Bisphosphonates in breast cancer
Coleman, R. E. (2005) · Annals of Oncology · doi:10.1093/annonc/mdi162 · Cited by 158
Leu, C., Luegmayr, E., Freedman, L. P., Rodan, G. A., & Reszka, A. A. (2005) · Bone · doi:10.1016/j.bone.2005.07.023 · Cited by 154
Mashiba, T., Mori, S., Komatsubara, S., Cao, Y., Manabe, T., Norimatsu, H., & Burr, D. B. (2005) · Journal of Bone and Mineral Metabolism · doi:10.1007/bf03026321 · Cited by 153
Ibandronate in osteoporosis: preclinical data and rationale for intermittent dosing
Bauss, F., & Russell, R. G. G. (2004) · Osteoporosis International · doi:10.1007/s00198-004-1612-7 · Cited by 148
Self-citationMcCloskey, E. V., Selby, P. L., Davies, M., Robinson, J., Francis, R. M., Adams, J. E., Kayan, K., Beneton, M. N. C., Jalava, T., Pylkkänen, L. H., et al. (2004) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.040116 · Cited by 145
Little, D. G., McDonald, M. M., Bransford, R., Godfrey, C., & Amanat, N. (2005) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.050712 · Cited by 145
Bonnick, S. L., Saag, K. G., Kiel, D. P., McClung, M. R., Hochberg, M. C., Burnett‐Bowie, S. M., Sebba, A. I., Kagan, R., Chen, E., Thompson, D. E., et al. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-2602 · Cited by 145
Antiresorptive dose-response relationships across three generations of bisphosphonates.
Sietsema, W. K., Ebetino, F. H., Salvagno, A. M., & Bevan, J. A. (1989) · PubMed · Cited by 139
Self-citationEffects of Teriparatide, Alendronate, or Both on Bone Turnover in Osteoporotic Men
Finkelstein, J. S., Leder, B. Z., Burnett‐Bowie, S. M., Wyland, J. J., Lee, H., de la Paz, A. V., Gibson, K. L., & Neer, R. M. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-0190 · Cited by 138
Little, D. G., Peat, R. A., McEvoy, A., Williams, P. R., Smith, E. J., & Baldock, P. A. J. (2003) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.2003.18.11.2016 · Cited by 131
Borah, B., Ritman, E. L., Dufresne, T. E., Jorgensen, S. M., Liu, S., Sacha, J. P., Phipps, R. J., & Turner, R. T. (2005) · Bone · doi:10.1016/j.bone.2005.03.017 · Cited by 130
Durchschlag, E., Paschalis, E. P., Zoehrer, R., Roschger, P., Fratzl, P., Recker, R. R., Phipps, R. J., & Klaushofer, K. (2006) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.060701 · Cited by 129
van Beek, E. R., Löwik, C. W. G. M., Ebetino, F. H., & Papapoulos, S. E. (1998) · Bone · doi:10.1016/s8756-3282(98)00120-3 · Cited by 125
Self-citationFleisch, H. A., Maerki, J., & Russell, R. G. G. (1966) · Experimental Biology and Medicine · doi:10.3181/00379727-122-31123 · Cited by 121
Self-citationPayne, D. J. (1973) · The Lancet · doi:10.1016/s0140-6736(73)90887-8 · Cited by 119
Fas/CD95 is associated with glucocorticoid-induced osteocyte apoptosis
Kogianni, G., Mann, V., Ebetino, F. H., NUTTALL, M. E., Nijweide, P. J., Simpson, H., & Noble, B. (2004) · Life Sciences · doi:10.1016/j.lfs.2004.04.048 · Cited by 117
Self-citationRecker, R. R., Weinstein, R. S., Chesnut, C. H., Schimmer, R. C., Mahoney, P., Hughes, C., Bonvoisin, B., & Meunier, P. J. (2004) · Osteoporosis International · doi:10.1007/s00198-003-1530-0 · Cited by 113
Wronski, T. J., Yen, C. ‐., & Scott, K. S. (1991) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.5650060410 · Cited by 106
Little, D. G., Smith, N. C., Williams, P. R., BRIODY, J. N., Bilston, L. E., Smith, E. J., Gardiner, E. M., & Cowell, C. T. C. T. (2003) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.2003.18.7.1300 · Cited by 105
Rogers, M. J., Ji, X., Russell, R. G. G., Blackburn, G. M., Williamson, M. P., Bayless, A. V., Ebetino, F. H., & Watts, D. J. (1994) · Biochemical Journal · doi:10.1042/bj3030303 · Cited by 102
Self-citationPharmacologic profile of zoledronic acid: A highly potent inhibitor of bone resorption
Green, J. R., & Rogers, M. J. (2002) · Drug Development Research · doi:10.1002/ddr.10071 · Cited by 100
Self-citationThe bisphosphonate ibandronate improves implant integration in osteopenic ovariectomized rats
Kurth, A. H. A., Eberhardt, C., Müller, S., Steinacker, M., Schwarz, M., & Bauss, F. (2005) · Bone · doi:10.1016/j.bone.2004.12.017 · Cited by 99
The long-term skeletal effects of EHDP in dogs
Flora, L., Hassing, G. S., Cloyd, G. G., Bevan, J. A., PARFITT, A. M., & Villanueva, A. R. (1981) · Metabolic Bone Disease and Related Research · doi:10.1016/0221-8747(81)90045-x · Cited by 95
van Beek, E. R., Löwik, C. W. G. M., Que, I., & Papapoulos, S. E. (1996) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.5650111016 · Cited by 94
Anti-Hip Fracture Efficacy of Bisphosphonates: A Bayesian Analysis of Clinical Trials
Nguyen, N. D., Eisman, J. A., & Nguyen, T. V. (2006) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.050903 · Cited by 91
Risedronate and alendronate suppress osteocyte apoptosis following cyclic fatigue loading
Follet, H., Li, J., Phipps, R. J., Hui, S. L., Condon, K. W., & Burr, D. B. (2006) · Bone · doi:10.1016/j.bone.2006.12.052 · Cited by 90
Brumsen, C., Papapoulos, S. E., Lips, P. T. A. M., Geelhoed-Duijvestijn, P. H. L. M., Hamdy, N. A. T., Landman, J. O., McCloskey, E. V., Netelenbos, J. C., Pauwels, E. K. J., Roos, J. C., et al. (2002) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.2002.17.6.1057 · Cited by 89
Mao, J., Mukherjee, S., Zhang, Y., Cao, R., Sanders, J. M., Song, Y., Zhang, Y., Meints, G. A., Gao, Y. G., Mukkamala, D., et al. (2006) · Journal of the American Chemical Society · doi:10.1021/ja061737c · Cited by 89
Bauss, F., Lalla, S., Endele, R., & Hothorn, L. A. (2002) · PubMed · Cited by 86
Zoledronic acid improves femoral head sphericity in a rat model of perthes disease
Little, D. G., McDonald, M. M., Sharpe, I. T., et al. (2005) · Journal of Orthopaedic Research® · doi:10.1016/j.orthres.2004.11.015 · Cited by 83
INORGANIC CHEMISTRY IN BIOLOGY AND MEDICINE
Martell, A. (1980) · Cited by 81
Risedronate Reduces the Risk of First Vertebral Fracture in Osteoporotic Women
Heaney, R. P., Zizic, T. M., Fogelman, I., Olszynski, W. P., Geusens, P., Kasibhatla, C., Alsayed, N., Isaia, G., Davie, M. W. J., & Chesnut, C. H. (2002) · Osteoporosis International · doi:10.1007/s001980200061 · Cited by 78
Mitchell, D. Y., Barr, W. H., Eusebio, R. A., Pallone, K. A., Duke, F. P., Russell, D. A., Nesbitt, J. D., Powell, J. H., & Thompson, G. A. (2001) · Pharmaceutical Research · doi:10.1023/a:1011024200280 · Cited by 78
Felsenberg, D., Miller, P. D., Armbrecht, G., Wilson, K., Schimmer, R. C., & Papapoulos, S. E. (2005) · Bone · doi:10.1016/j.bone.2005.05.004 · Cited by 76
Eastell, R., Hannon, R. A., Garnero, P., Campbell, M. J., & Delmas, P. D. (2007) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.07090b · Cited by 76
Trechsel, U., Stutzer, A., & Fleisch, H. A. (1987) · Journal of Clinical Investigation · doi:10.1172/jci113257 · Cited by 74
Wilkinson, J. M., Eagleton, A. C., Stockley, I., Peel, N. F. A., Hamer, A. J., & Eastell, R. (2004) · Journal of Orthopaedic Research® · doi:10.1016/j.orthres.2004.06.004 · Cited by 73
Cremers, S., Sparidans, R. W., den Hartigh, J., Hamdy, N. A. T., Vermeij, P., & Papapoulos, S. E. (2002) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-001-0411-8 · Cited by 71
Miller, P. D. (2005) · Current Osteoporosis Reports · doi:10.1007/s11914-005-0018-6 · Cited by 70
PTH and interactions with bisphosphonates.
Ja, G., Kneissel, M., Js, T., & Mosekilde, L. (2000) · PubMed · Cited by 67
Bisphosphonate binding affinity as assessed by inhibition of carbonated apatite dissolutionin vitro
Henneman, Z. J., Nancollas, G. H., Ebetino, F. H., Russell, R. G. G., & Phipps, R. J. (2007) · Journal of Biomedical Materials Research Part A · doi:10.1002/jbm.a.31599 · Cited by 64
Self-citationLiberman, U. A., Hochberg, M. C., Geusens, P., SHAH, A., Lin, J. T., Chattopadhyay, A., & Ross, P. D. (2006) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2006.01148.x · Cited by 53
Papapoulos, S. E., & Schimmer, R. C. (2007) · Postgraduate Medical Journal · doi:10.1136/ard.2006.064931 · Cited by 47
Bauss, F., Schenk, R., Hört, S., Müller‐Beckmann, B., & Sponer, G. (2004) · Journal of Pharmacological and Toxicological Methods · doi:10.1016/j.vascn.2003.11.003 · Cited by 46
Allen, M. R., & Burr, D. B. (2007) · Osteoporosis International · doi:10.1007/s00198-007-0451-8 · Cited by 45
Bijvoet, O. L. M. (1995) · Elsevier eBooks · Cited by 38
The use of cyclical etidronate in osteoporosis: changes after completion of 3 years treatment
Fairney, A., Kyd, P., Thomas, E., & Wilson, J. (1998) · Lara D. Veeken · doi:10.1093/rheumatology/37.1.51 · Cited by 15
Bisphosphonates and γδ t-cells: New insights into old drugs
Thompson, K., & Rogers, M. J. (2006) · BoneKEy-Osteovision · doi:10.1138/20060224 · Cited by 12
Self-citation
Cited by
Denosumab for Prevention of Fractures in Postmenopausal Women with Osteoporosis
Cummings, S. R., Martin, J. S., McClung, M. R., Siris, E. S., Eastell, R., Reid, I. R., Delmas, P., Zoog, H. B., Austin, M., Wang, A., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0809493 · Cited by 3,489
Ruggiero, S. L., Dodson, T. B., Fantasia, J., Goodday, R., Aghaloo, T., Mehrotra, B., & O'Ryan, F. (2014) · Journal of Oral and Maxillofacial Surgery · doi:10.1016/j.joms.2014.04.031 · Cited by 2,905
Bisphosphonates: The first 40years
Russell, R. G. G. (2011) · Bone · doi:10.1016/j.bone.2011.04.022 · Cited by 1,124
Self-citationOsteoporosis treatment: recent developments and ongoing challenges
Khosla, S., & Hofbauer, L. C. (2017) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(17)30188-2 · Cited by 1,019
Surface Modification Using Phosphonic Acids and Esters
Queffélec, C., Petit, M., Janvier, P., Knight, D. A., & Bujoli, B. (2012) · Chemical Reviews · doi:10.1021/cr2004212 · Cited by 868
Metadata
- Authors
- Russell, R. G. G., Watts, N. B., Ebetino, F. H., & Rogers, M. J.
- Venue
- Osteoporosis International
- Published
- 2008-01-24
- Volume
- 19
- Issue
- 6
- Pages
- 733-759
- ISSN
- 0937-941X (ISSN-L)
- 1433-2965
- OpenAlex
- W2134304734
- Cited by
- 1,411
- References
- 144
- FWCI
- 41.42
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.